A model-informed approach to accelerate the clinical development of cofrogliptin (HSK7653), a novel ultralong-acting dipeptidyl peptidase-4 inhibitor.
Dongyang LiuFangrui CaoIok Ian KongQinghe WuFangqiong LiHaiyan LiDongyang LiuPublished in: Diabetes, obesity & metabolism (2023)
Successful waiver approval for the phase 2b dose-finding study was achieved through model-informed recommendations, facilitating the clinical development of HSK7653 and other DPP-4 inhibitors.
Keyphrases